The dual role of mutant p53 protein in chemosensitivity of human cancers

Anticancer Research

Volumn 16, Issue 6 B, 1996, Pages 3845-3848

  Mueller, Heinz ^a,b   Eppenberger, Urs ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY WOMEN S HOSPITAL   (Switzerland)

Author keywords

Cancer; Chemosensitivity; p53

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DNA; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; PACLITAXEL; PENTOXIFYLLINE; PROTEIN P53; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER; CELL DEATH; CHEMOSENSITIVITY; CYTOTOXICITY; DNA CROSS LINKING; DNA DAMAGE; DNA REPAIR; DRUG EFFECT; DRUG EFFICACY; GENE MUTATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

APOPTOSIS; DNA DAMAGE; DNA REPAIR; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; GENES, P53; HUMANS; MUTATION; NECROSIS; NEOPLASM PROTEINS; NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030485536     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Tormey DC: Adriamycin in breast cancer. An overview of studies. Cancer Treat Rep 6:319-327, 1975.
2. Henderson IC: Chemotherapy for advanced disease. In: Harris JR. Hellman S, Hendersor IC, et al (eds): Breast Diseases. Philadelphia, Lippincott 1987. p 434.
3. Simon SM: Cell biological mechanisms of multidrug resistance in tumors Proc Natl Acad Sci USA 91: 3497-3504, 1994.
4. Cole SP, Bhardwaj G, Gerlach JH et al: Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258: 1650-1654, 1992.
5. Zaman GJ, Flens MJ, van Leusden MR et al: The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc Natl Acad Sci USA 91: 8822-8826, 1994.
6. Scheffer GL, Nijngaard PLJ, Flens MJ et al: The drug resistance -related protein LRP is the human major vault protein. Nature Medicine 1:578-582, 1995.
7. Mayer R, Kartenheck J, Buchler M et al: Impression of the MRP gene-encoded conjugale export pump in liver and its selective absence from the canalicular membrane in transport-deficient mutant hepatocytes. J Cell Biol 131:137-150, 1945.
8. Darzynkiewicz Z: Apoptosis in antitumor strategies: Modulation of cell cycle or differentiation. J Cellular Biochem. 58:151-159, 1995.
9. Kaufman S H: Induction of endonuelcolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, compthothecin, and other cytotoxic antitumor drugs. A coutionary note. Cancer Res 49: 5870-5878, 1989
10. Evans DL, Dive C: Effects of cisplatin on the induction of apoptosis in proliferating hepaloma cells and nonproliferating immature thymocytes. Cancer Res 53: 2133-2139, 1993.
11. Ormerod MG, O'Neil CFO, Robertson D, Harrup KR: Cisplatin induces apoptosis in human ovarian carcinoma cell line without a concomitant internucleosomal degradation of DNA. Exp Cell Res 211:231-237, 1994.
12. Marx J: Cell death studies yield cancer clues. Science 259:760-761, 1993.
13. Milner J: DNA damage. p53 and anticancer therapies. Nature Medicine 1:879-880, 1995.
14. Koechli OR, Schaer GN, Seifert B et al: Mutant p53 protein associated with chemosensitivity in breast cancer specimens. Lancet 144: 1647-48, 1994.
15. Rutz HP: Cancer therapy meets p53 New Engl J Med 331: 1314-15, 1995.
16. Makris A, Powels T J, Dowsett M and Allied C: p53 protein over-expression and chemosensitivity in breast cancer, Lancet 345: 1181-82, 1995.
17. Mathieu M-C, Koseiclny S, Bihan M-L et al: p53 protein overexpression and chemosensitivity in breast cancer. Lancet 345: 1182, 1995.
18. Petty RD, Cree IA, Sutherland LA et al: Expression of the p53 tumour suppressor gene product is a determinant of chemosensitivity. Hiochem Biophys Res Commun 199:264-70, 1994.
19. Lowe SW, Ruley H E, Jacks T and Housman DE: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74:957-967, 1993.
20. Lowe SW, Bodis S, McClatchey A et al: p53 status and the efficacy of cancer therapy in vivo Science 266:807-810, 1994.
21. Fan S, El-Deiry WS, Bac I, Freeman J et al: p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res 54: 5824-5830, 1994.
22. Fan S, Smith ML, Rivet DJ et al: Disruption of p53 function sensitizes breast cancer MCF-7 cells to eisplatin and pentoxifylline. Cancer Res 55: 1649-1654, 1995.
23. Wahl AF, Donaldson KL, Fairchild C et al: Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nature Medicine 2:72-79, 1996.
24. Prioleau J and Schnitt SJ: p53 antigen loss in stored paraffin slides. New Engl J Med. 332: 1521-22, 1995.
25. Goldsmith ME, Gudas JM, Schneider F., Cowan KH: wild type p53 stimulates expression from the human multidrug resistance promoter in a p53-negative cell line. J Biol Chem 270: 1894-1898, 1995.